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Background: Cognitive decline after cerebrovascular stroke has adverse outcome consequences. 
Since some vascular causes can be prevented and treated, the identiﬁ  cation of stroke-related 
cognitive impairment is a challenge. Patients with cognitive impairment and vascular diseases 
exhibit higher homocysteine (Hcy) concentrations. Whether Hcy is an independent risk factor 
for cognitive impairment after stoke is still in question. The objectives of this study were to 
determine: 1) the relative frequency of ﬁ  rst-ever post-stroke dementia (PSD) (three months after 
onset) in a consecutive sample of our population, 2) the risk factors associated with PSD, and 
3) the relationship between Hcy levels and PSD.
Methods: Eighty-one inpatients with ﬁ  rst-ever stroke were prospectively evaluated with a 
neuropsychological battery and event-related evoked potentials (P300) at onset and then after 
three months. A wide range of demographic, clinical, radiological and laboratory variables were 
examined. PSD was diagnosed if the clinical presentation fulﬁ  lled DSM-IV criteria of vascular 
dementia, the patient scored  21 on Mini Mental State Examination (MMSE) and  67 points 
on Cognitive Abilities Screening Instruments (CASI).
Results: PSD was diagnosed in 21%. PSD was signiﬁ  cantly associated with increasing age, 
low levels of education, large sized and lacunar infarctions, severity of stroke, prolonged P300 
latency, smoking, hypertension, and elevated Hcy levels. High Hcy levels increased the odds 
ratio of PSD after adjustment of signiﬁ  cantly relevant variables including age, smoking, size 
of infarction, and carotid stenosis.
Conclusions: Cognitive decline is common after stroke. The results of this study indicate that 
PSD may result from stroke and its related risk factors including possible direct association with 
high Hcy levels. Better knowledge of the risk factors for PSD should increase the effectiveness 
of preventive strategies in patients with this condition.
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Introduction
Cerebrovascular stroke (CVS) is the third leading cause of death and a major source 
of disability and mortality.1 CVS may result in quantiﬁ  able decrease in quality of life 
which is determined not only by the neurological deﬁ  cits but also by impairment of 
cognitive functions.2 Post-stroke dementia (PSD) is a subtype of vascular dementia. 
Vascular dementia is the second most common type of dementia after Alzheimer’s 
disease (AD).3 PSD is deﬁ  ned as the presence of dementia identiﬁ  ed at three months 
after an acute, either recurrent or ﬁ  rst-ever, stroke.4 The frequency of PSD has 
been found to be higher than previously expected, and a stroke increases the risk of 
dementia 4 to 12 times.5,6 The prevalence of PSD among recurrent or ﬁ  rst-ever stroke 
patients varies from 6% to 55%.1,7–9 Not all individuals with stroke develop demen-
tia. In addition, the prevalence of PSD may decline years after stroke. Snaphaan and 
colleagues9 reported that the prevalence of post-stroke memory dysfunction varied 
from 23% to 55% three months after stroke, which declined from 11% to 31% one 
year after stroke. A further study of a stroke cohort indicated that  30% of subjects Neuropsychiatric Disease and Treatment 2009:5 104
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who had mild cognitive impairments between 0–6 months 
after stroke improved and were classiﬁ  ed as cognitively intact 
by 12 to 18 months.10 These evidences indicate that PSD 
may be reversible in a substantial proportion of patients. In 
contrast, some studies found that not only the risk of PSD 
is high immediately after stroke but also remains higher 
in patients nondemented three months after stroke.11 Even 
among patients who remain cognitively intact, hospital-based 
and population-based studies have revealed a signiﬁ  cant risk 
for developing delayed dementia.5,12,13 In community-based 
studies, the prevalence of PSD is about 30% and the incidence 
of new onset dementia after stroke increases from 7% after 
one year to 48% after 25 years.6
The pathophysiology of PSD is multifactorial and its risk 
factors are still incompletely understood. In the past decade, 
raised plasma homocysteine (Hcy) has emerged as a potential 
risk factor for development of vascular diseases including 
coronary heart diseases and stroke.14,15 In addition, informa-
tion has been emerging regarding a connection between Hcy 
metabolism and cognitive function, from mild cognitive 
decline to vascular dementia and AD.4,16 Only very few data 
are available regarding the direct impact of Hcy on cognitive 
in stroke patients.17 The direct relationship between variables 
related to post-stroke cognitive impairment and Hcy levels 
has to be studied. Also the results examining the relationship 
between Hcy and different stroke subtypes are inconsistent, 
controversial and there is no consensus about them. Since 
the possibility that Hcy is a risk factor for cognitive impair-
ment after stroke and can be prevented and treated by vitamin 
supplementation,18 the identiﬁ  cation of Hcy-related cognitive 
impairment after stroke is essential.
Aim of the work
This hospital-based study was done to determine 1) the 
relative frequency of ﬁ  rst-ever PSD (three months after onset) 
in a sample of consecutive stroke patients of our population, 
2) the risk factors of PSD, including demographic and clinical 
determinants, stroke characteristics including size, location, 
type, etiology, severity, and vascular risk factors, and 3) the 
relationship between total Hcy (tHcy) levels and cognitive 
decline after stroke.
Materials and methods
Included in this study were consecutive in-patients with recent 
CVS, aged 40–75 years, within seven days of stroke onset. 
Stroke was deﬁ  ned as acute onset of focal neurological deﬁ  -
cits attributable to cerebrovascular disease and documented 
by computerized tomography (CT) or magnetic resonance 
imaging (MRI). Control healthy subjects (n = 40) were 
matched for age, sex, educational level, and socioeconomic 
status. Patients were recruited from the acute stroke unit of 
the Department of Neurology, Assiut University Hospital, 
Assiut, Egypt over a period of one year. Written consents 
were obtained from patients or their relatives after having 
received oral or written information about the study. The local 
ethical committee of Assiut University Hospital approved 
the study. Inclusion criteria for the study were: 1) Egyptian 
ethnicity; 2) well documented clinical presentation and CT 
and/or MRI scan of the brain after ﬁ  rst acute stroke occurring 
within seven days before admission. Ischemic or hemorrhagic 
acute strokes and history of transient ischemic attacks were 
included; 3) ability to give consent or the availability of 
relative to give proxy consent to participate in the study; 
and 4) ability to have informed knowledge of the patients’ 
earlier and current cognitive functioning. Exclusion criteria 
included: 1) persistent disturbed level of consciousness; 
2) persistent aphasia; 3) history of pre-stroke cognitive 
impairment; 4) missing baseline Informant Questionnaire on 
Cognitive Decline in the Elderly (IQCODE), which makes 
use of the informant’s knowledge of both the person’s earlier 
and current cognitive functioning; 5) history of psychosis 
or other neurological diseases involving the central nervous 
system that interfere with cooperation of patient; 6) brain 
ischemia due to cardiorespiratory arrest; 7) subarachnoid 
hemorrhage; 8) systemic diseases known to involve 
the central nervous system (as renal and liver diseases, 
systemic lupus erythematosus, and AIDS); 9) severe sensory 
impairment (blindness and deafness); 10) cancer discovered 
in the previous ﬁ  ve years; and 11) patients with history of 
severe head trauma or neurosurgical operation at any time 
before stroke.
A standard stroke evaluation was conducted on admis-
sion in 370 consecutive patients admitted to stroke unit: 
270 of those did not meet the selection criteria; 100 met the 
selection criteria; 12 refused to participate in the study; three 
died before the second assessment; and four had impaired 
cognitive function prior to stroke (pre-stroke dementia) as 
documented by IQCODE.
During the ﬁ  rst week of stay in the stroke unit, patients’ 
relatives gave an account on the patients’ cognitive function 
by completing the IQCODE. It is a 26-item questionnaire that 
rates changes in everyday situations where a person has to use 
his memory or intelligence.19 Each situation is rated by the 
informant for amount of change over the previous 10 years, 
using a 5-point scale (1 = much better, 5 = much worse). The 
IQCODE is generally scored by averaging the ratings across Neuropsychiatric Disease and Treatment 2009:5 105
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the 26 situations. A person who has no cognitive decline will 
have an average score of 3, while scores of  3 indicate cog-
nitive decline. IQCODE has good crosscultural applicability 
and is used as a screening tool for dementia in a population 
with large variation in educational backgrounds.
Assessment procedures
Demographic and clinical characteristics
Baseline medical, neurological and psychiatric assessments 
were done within one week of admission. Demographic data 
included: age, sex, educational level, occupation, family his-
tory of dementia, family interview of pre-morbid status and 
history of stroke vascular risk factors (as smoking habits, 
hypertension, diabetes mellitus, hypercholesterolemia, atrial 
ﬁ  brillation [AF], ischemic heart disease [IHD], and transient 
ischemic attacks). The educational level of the patients was 
measured as the total numbers of years of formal education 
each patient received (illiterate and educated for  8 years 
or  8 years). All patients were subjected to cardiac exami-
nation included an electrocardiogram (ECG) and echocar-
diography of the heart.
Laboratory measurements
Laboratory measurements included: serum tHcy, blood 
sugar (fasting and post-prandial), renal and liver functions 
and lipogram (serum total cholesterol [TC], triglycerides 
[TG], low-density lipoprotein cholesterol [LDL-c], high-
density lipoprotein cholesterol [HDL-c]). Serum levels of 
TC, TG, HDL-c, and LDL-c were measured by an enzymatic 
colorimetric method using the autoanalyzer Hitachi 911 
(Boehringer Mannheim, Indianapolis, IN, USA). tHcy was 
analyzed in blood using ELISA technique (Axis® homocys-
teine ElA package insert kits, IBL GmbH-Flughafenstrasse 
52A-D-22335, Hamburg, Germany). The cut-off value of 
tHcy was 12 μmol/L.
Neuroimaging characteristics
A noncontrast CT brain scan examination was done for all 
patients while a MRI brain scan was done in selected patients 
(when CT revealed no abnormalities). The following radio-
logical data were collected: presence of hemorrhage, infarct 
subtypes, number, size, location (deep versus superﬁ  cial loca-
tion), laterality of lesions and cerebral circulation involvement 
(territorial or lacunar). The stroke size was deﬁ  ned as: a) large 
if the infarction involved more than half a cerebral hemi-
sphere; b) small if the infarction involved was  15 mm in 
diameter, but less than one half of a cerebral hemisphere; and 
c) lacunar if the infarction was  15 mm in diameter. Lacunar 
infarcts are localized to the territories of deep perforating 
arteries. Lesions were classiﬁ  ed as superﬁ  cial when they 
affected the cortical surface and/or subcortical white matter 
whereas deep lesions involved the basal ganglia, internal 
capsule, or thalamus. Patients with anterior circulation infarcts 
were associated with carotid arterial territory (left or right, 
anterior or middle cerebral arteries). Those associated with 
vertebrobasilar arterial territory were grouped under posterior 
circulation infarcts. The presumed causes of ischemic stroke 
were deﬁ  ned at discharge, according to the TOAST criteria 
(The Trial of Org 10172 in Acute Stroke Treatment) which 
categorizes ischemic stroke into ﬁ  ve subtypes based on cause: 
large-artery atherosclerosis, small-artery occlusion (lacunes), 
cardioembolic stroke, stroke of other determined cause, and 
stroke of undetermined cause.20 The TOAST classiﬁ  cation 
system for stroke has gained wide acceptance for both clinical 
and research purposes eg, stroke risk assessment studies as 
this study.
Carotid color duplex examination
Examination of the intima-media thickness of the carotid 
arteries (CA-IMT) was manually performed twice to all 
participants by the same experienced radiologist using a 
5MHZ linear transducer of a color duplex ﬂ  ow imaging 
system (Acuson 128 XP, Acuson Corporation, Mountain 
View, CA, USA), which operates in several modes: real 
time B, color Doppler and spectral Doppler modes. We 
investigated the degree of stenosis in the common carotid 
artery (CCA). Signiﬁ  cant stenosis of the cervical arteries, 
deﬁ  ned as a narrowing of  30% of the lumen.21
Cognitive assessment
A detailed neuropsychological assessment was done twice for 
all patients, within one week of stroke onset and after three 
months. Normative data for these tests were also established 
twice in the control group.
A set of standardized neuropsychological tests which are 
sensitive for mild cognitive impairment and covering different 
cognitive domains, were selected. Each patient was tested on 
three separate days and at separate occasions in the same day 
to complete the total battery of testing and avoid exhaustion of 
stroke patients. The primary outcome variables for cognition 
were scored by the use of the following instruments: 1) Mini-
Mental State Examination (MMSE),22 a widely used scale 
for the screening test for dementia. It consists of a variety of 
questions grouped into seven categories, each representing 
a different cognitive domain or function (orientation to time, 
orientation to place, repetition of words, attention, calculation, Neuropsychiatric Disease and Treatment 2009:5 106
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recall of words, language, and visual construction). It has a 
maximum score of 30 points. As most of the subjects of the 
present study were illiterate or with low education levels, 
the two points testing reading and writing were excluded, 
and the full score was calculated as 28 instead of 30 points. 
The lower value for regarding a subject as dementia suspect 
was  21 instead of  23 points. MMSE takes 5–10 minutes 
to administer. 2) Cognitive Abilities Screening Instruments 
(CASI)23 is a 25-item test which provides quantitative assess-
ment on attention, concentration, orientation, memories 
for past knowledge and present input, language or verbal 
ﬂ  uency, drawing, constructional praxis, writing abilities, list 
generating abilities, abstract thinking, judgment, and every-
day problem solving skills. The CASI is more comprehensive 
than most screening tests of cognitive abilities. The cut off 
of dementia was  67. It takes 45–60 minutes to administer. 
3) Wechsler Memory Scale-Revised (WMS-R)24 is useful 
for mild memory impairment, where sensitivity is needed. 
Selected tests included: digit forward, digit backward, mental 
control, associate learning, logical memory I and II and visual 
reproduction I and II. It takes 25–30 minutes to administer.
Neurophysiological assessment
Testing for event-related potentials (ERPs) was done on a 
separate day after completion of neuropsychological battery 
of testing. It takes at least one and half hours to administer (as 
repetition of testing was needed to assure accuracy). Testing 
for ERPs was done twice for patients and controls (within one 
week and three months after stroke onset). ERPs are series 
of scalp waves that are extracted from the electroencephalo-
gram (EEG) by time domain analysis and averaging of EEG 
activity following multiple stimulus repetitions. They were 
elicited with an auditory discrimination task paradigm by 
presenting a series of binaural 1.000 Hz (standard) versus 
2,000 Hz (target) tones at 70 dB with a 10 millisecond rise/
fall and 40 millisecond plateau time. Tones were presented at 
a rate of 1.1 per second, with target tones occurring randomly 
with a 0.2 probability. Subjects were sitting with their eyes 
closed and were instructed to mentally count the number 
of the target but not the frequent tones, and then asked to 
report the number of target tones counted at the end of each 
run. Potentials were recorded from scalp electrodes placed 
at Cz and were referred to linked ears. Filter settings were 
0.5 and 70 Hz. Responses to 30 target and 120 nontarget tones 
were obtained in each trial. Separate averages for target and 
nontarget tones were obtained. Before recording, subjects 
were familiarized with the two tones and instructed to press 
a button when they heard target tones. The obtained ERPs 
were subdivided into early or sensory-evoked components 
(eg, P100, N100, P200, N200), which emerge within the 
ﬁ  rst 100–200 millisecond after stimulus onset and basically 
reﬂ  ect stimulus detection and auditory evoked brainstem 
potentials, and later or cognitive-related components (eg, 
P300).25 Latencies of each event-related component (N100, 
P200, N200, and P300) were measured. P300 latency was 
measured as the major positive peak after N200, within a 
range of 250–500 milliseconds. The amplitudes of N200 
and P300 were measured peak to peak from the negative 
component just before the wave to the maximum posi-
tive peak of the wave. P300 is believed to index stimulus 
signiﬁ  cance and the amount of attention allocated to the 
eliciting stimulus event, being maximal to task-relevant or 
attended stimuli and being absent or small to task-irrelevant 
or unattended stimuli.25
Assessment of motor and functional disabilities
The degrees of patients’ motor and functional disabilities 
were determined using Scandinavian Stroke Scale (SSS)26 and 
Barthel Index (BI).27 Each takes  10 minutes to administer. 
Assessment of depression was done using Hamilton Depression 
Rating Scale.28 It is a 21-item version test measuring the 
severity of depressive symptoms. The cut off point of depres-
sion in this scale is  17. It takes ∼15 minutes to administer.
Follow up assessment after three months
Patients were regularly followed up monthly through the 
out-patient neurology clinic of the University Hospital to 
control for the therapeutic measures and those for secondary 
prevention of CVS. Both patients and control subjects were 
similarly assessed twice, three months apart, using the 
same battery of neuropsychological and neurophysiological 
assessment. Vascular dementia was diagnosed according 
to Diagnostic and Statistical Manual of Mental Disorders 
(DSM-IV).29 DSM-IV deﬁ  nes the predominant disturbance as 
a clinically deﬁ  cient in cognition or memory that represents 
a signiﬁ  cant change from previous level of function. PSD 
was diagnosed if the clinical presentation fulﬁ  lled DSM-IV 
criteria of vascular dementia as well as when the subject 
scored  21 on MMSE and  67 points on CASI. WMS-R 
was used to assess selected aspects for memory other than 
that in MMSE and CASI.
Statistical analysis
Data were expressed as means ± SD unless otherwise stated. 
Calculations were done with the statistical package SPSS 
for Windows (version 10.0; SPSS Inc., Chicago, IL, USA). Neuropsychiatric Disease and Treatment 2009:5 107
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Patients were divided into two groups according to the 
diagnosis of dementia. Descriptive statistics was used to 
compare baseline characteristics using two-tailed Student 
t test for quantitative variables for contrast of means and χ2 
test for comparison of proportions. Nonparametric methods 
were used to evaluate the number of the parameters that were 
not normally distributed. Mann–Whitney U-test (MW) was 
used to compare unpaired data that had skewed distribution 
(as TC, LDL-c, HDL-c, TG, tHcy, and P300 amplitude) while 
the Wilcoxon signed-rank test was utilized to compare paired 
data (for cognitive performance results of neuropsychological 
testings). Logistic regression analyses were used to assess 
the relation between Hcy and other relevant risk factors. 
A univariate logistic regression was ﬁ  rst performed using 
Hcy as a dependant variable and demographic, clinical and 
vascular risk determinants of PSD as independent variables. 
Variables that showed signiﬁ  cant association with increased 
Hcy levels in the univariate analysis (ie, p   0.05) were 
used in multiple logistic regression analysis to determine the 
independent relation between Hcy and that variables. Results 
were given as odds ratio (OR) for risk factors, with 95% 
conﬁ  dence interval (CI). For all tests, values of P   0.05 were 
considered statistically signiﬁ  cant.
Results
The ﬁ  nal sample was 81 patients, 54 males and 27 females, 
with mean age 57.7 ± 5.19 years (range: 40–75 years). 
Seventy-six (93.8%) patients had educational level below 
eight years. Sixty-eight (84%) patients had ischemic stroke 
and 13 (16%) had hemorrhagic stroke. Twenty patients 
(24.7%) had stroke of dominant hemisphere and 61 (75.3%) 
had stroke of the nondominant hemisphere. The mean score 
of Scandinavian Stroke Scale (SSS) was 41.4 ± 11.8 and 
59.3 ± 26.3 for BI at the acute phase of stroke. Seventeen 
patients (21%) fulﬁ  lled the criteria of PSD at three months 
after stroke. The frequency of dementia in ischemic and 
hemorrhagic strokes were 76.5% (or 13/17) and 23.5% (or 
4/17) of patients, respectively. The vascular lesions contrib-
uting to PSD were territorial infarcts or gross hemorrhages 
in 15 cases (88.2%) and small vessel lacunar lesions in six 
(35.3%). Depression was present in 29.4% and 23.4% of 
patients with and without PSD. At follow up, stroke patients 
with depression had signiﬁ  cantly greater impairment of motor 
and functional abilities than nondepressed stroke patients.
Table 1 showed the distribution of demographic and 
clinical characteristics according to presence or absence of 
dementia. Compared with nondemented patients, patients 
with PSD were signiﬁ  cantly older (p = 0.053), had low levels 
of education (p = 0.003) and disturbed level of consciousness 
at the onset (p = 0.045). While no signiﬁ  cant association was 
identiﬁ  ed between PSD and sex, However, when patients 
classiﬁ  ed according to age groups (40–54, 55–64, and 65–
75 years), there was a signiﬁ  cant association between age and 
dementia in females (p = 0.003) and not in males. The majority 
of vascular risk factors were more frequent among patients 
with PSD, such as current smoking (p = 0.054), hypertension 
(p = 0.007), AF (p   0.0001), IHD (p   0.0001), family 
history of dementia (p   0.0001), elevated Hcy levels 
(p   0.0001), and carotid stenosis (p = 0.024). At onset SSS 
(p = 0.019) and BI scores (p = 0.026) were worse in PSD.
Table 2 showed the distribution relationship between 
the ﬁ  ndings of neuroimaging and stroke-related variables 
according to presence and absence of dementia. Large size 
infarctions (P = 0.001), territorial infarctions in the distribu-
tion of left or right carotid arteries (P = 0.05) and dominant 
hemispheric lesions (P = 0.01) were more frequent in PSD. 
Patients with PSD had signiﬁ  cantly more large artery athero-
sclerosis (P = 0.01), cardioembolic (P = 0.001) and hemor-
rhagic (P = 0.01) strokes than did nondemented patients.
Table 3 showed the results of neuropsychological testing. 
At three months after stroke onset, patients demonstrated 
signiﬁ  cant reduction in the total score for MMSE (p   0.01) 
and CASI (p   0.05). Signiﬁ  cant reductions were demon-
strated with logical memory (p   0.05), attention (p   0.05), 
orientation (p   0.01), associate learning (p   0.001), 
drawing (p   0.05), abstract thinking (p   0.05), and visual 
reproduction (p   0.05).
Table 4 showed the resulting ERPs (latencies and ampli-
tudes). At three months after the onset of stroke, patients 
demonstrated signiﬁ  cant prolongation in the latencies of 
N100, N200, P200, and P300 (p   0.001). No gender dif-
ference in ERPs was identiﬁ  ed.
Cognitive impairment as determined by CASI scoring 
was associated with age (r = −0.255, p   0.05), level of 
education (r = 0.657, p   0.001), large-sized infarctions 
(r = −0.655, p   0.001), lacunar infarctions (r = −0.685, 
p   0.001), BI (r = −0.465, p   0.05), P300 latency 
(r = −0.540, p   0.001), current smoking (r = −0.465, 
p   0.01), hypertension (r = −0.365, p   0.05), and tHcy 
levels (r = −0.743, p = 0.0001).
As shown in Table 5, tHcy levels were stratiﬁ  ed into 
low ( 12 μmol/L) and high ( 12 μmol/L) groups. Older 
ages (p = 0.005), sizable infarctions (p   0.0001), carotid 
stenosis (p   0.0001), smoking (p = 0.05), presence PSD 
(p   0.0001) and delayed P300 latency (p   0.0001) were 
signiﬁ  cantly associated with elevated tHcy levels.Neuropsychiatric Disease and Treatment 2009:5 108
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In multiple logistic regression analysis, after adjustment 
of age, the odds ratio (95% Cl) of PSD was 4.5 (1.5–13.5) 
in the group with high Hcy compared with 2.7 (1.2–8.0) 
for the low risk group (p = 0.01). Furthermore, after adjust-
ment of smoking, the odds ratio of cognitive impairment 
(95% Cl) was 4.7 (1.7–14.2) in the group with high Hcy and 
2.5 (1.5–7.3) in the low risk group (p = 0.02). After adjust-
ment for size of the infarction, the odds ratio of PSD (95% 
Cl) was 4.8 (1.8–14.7) in the group with high Hcy and 2.5 
(1.2–6.5) in the low risk group (p = 0.01). After adjustment 
for carotid stenosis, the odds ratio of PSD (95% Cl) was 5.9 
(2.8–18.5) in the group with high Hcy and 3.5 (1.5–9.5) in 
the low risk group (p = 0.005).
Discussion
Cerebrovascular stroke (CVS) is a risk factor for impaired 
cognitive functioning. Not only physical handicapping but 
also cognitive dysfunction after CVS can adversely inﬂ  uence 
Table 1 Demographic, clinical, vascular risk factors and functional status of demented and nondemented patients
Variables Demented (n = 17) Nondemented (n = 64) P-value
Age (years)
Range 40–75 40–75
mean + SD 65.5 ± 9.2 56.9 ± 5.3 0.053
Males/females (n = 27/54) 11/6 43/21 0.847
Level of education1
Illiterate 14 (82.4%) 42 (67.7%) 0.003
Less than eight years of education 3 (17.6%) 17 (36.6%)
More than eight years of education 0 5 (7.8%)
Disturbed consciousness at 
onset
6 (35.29%) 13 (20.3%) 0.045
Current smoking 13 (76.5%) 24 (37.5%) 0.054
Hypertension 10 (58.8%) 23 (35.9%) 0.007
Diabetes mellitus 10 (58.8%) 31 (48.4%) 0.334
Transient ischemic attacks 2 (11.8%) 21 (32.8%) 0.087
Cardiac disease
Atrial ﬁ  brillation 5 (29.4%) 1 (1.6%)  0.0001
Ischemic heart disease 6 (35.3.2%) 11 (17.2%)  0.0001
Family history of dementia 6 (35.3%) 1 (1.6%)  0.0001
Family history of stroke 2 (11.8%) 6 (9.4%) 0.769
Scandinavian Stroke Scale 35.4 ± 13.9 42.9 ± 10.8 0.019
Barthel Index scale 46.7 ±2 8.6 62.7 ± 24.9 0.026
Presence of depression 5 (29.4%) 15 (23.4%) 0.412
Creatinine clearance, mL/min 52.3 ± 18.0 55.7 ± 14.5 0.620
Packed cell volume, % 36.3 ± 4.8 37.8 ± 3.5 0.750
Homocysteine
Hyperhomocysteinemia 8 (47.05%) 14 (22%)  0.0001
Mean Hcy level, μmol/L 17.9 ± 8.0 12.3 ± 3.3  0.0001
Lipid proﬁ  le
Total cholesterol, mg/dl 81.9 ± 52.2 183.9 ± 45.1 0.870
Triglycerides, mg/dl 112.5 ± 48.9 121.3 ± 53.7 0.545
LDL-C, mg/dl 104.35 ± 46 98.3 ± 45.4 0.620
HDL-C, mg/dl 54.2 ± 27.8 64.7 ± 34.1 0.242
Carotid stenosis ( 30%) 8 (47.1%) 13 (20.3%) 0.024
Notes: Data are expressed as mean ± SD and number (%); signiﬁ  cance is between demented and nondemented groups; 1signiﬁ  cance between illiterate/less than eight years 
of education and more than eight years of education; signiﬁ  cance is set at p-value   0.05.
Abbreviations: Hcy, homocysteine; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SD, standard deviation.Neuropsychiatric Disease and Treatment 2009:5 109
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the long-term survival after adjusting other predictors for 
stroke mortality.1,2 The frequency of dementia after CVS 
varies between studies. The results of this study revealed that 
dementia affects up to 21% of stroke survivors three months 
after stroke. Jonkman and colleagues30 reported that the 
incidence of cognitive impairment three months after stroke 
was 35%–37%. Pohjasvaara and colleagues31 reported PSD 
in 31.8%. Madureira and colleagues32 found the frequency of 
PSD to be only 6%. Our ﬁ  nding falls between these extremes 
and is comparable to most of the literatures. The difference 
of prevalence of PSD among various studies depends on the 
study design (eg, nonprospective or nonconsecutive samples) 
and the population studied, eg. demographic characteristics 
(as age, gender, and ethnicity), criteria used for the diagnosis 
of dementia, clinical manifestations, the preexisting cogni-
tive level, lesion-related and radiological-associated factors 
as exclusion of hemorrhage or recurrent stroke, white matter 
changes, presence of cerebral atrophy, vascular risk factors, 
the time interval between the stroke and the neuropsycho-
logical assessment and length of follow-up.1,4,7,8,12,30–33 In an 
exploratory effort, Tatemichi and colleagues7 reported PSD in 
16% (116/726) of patients in a stroke cohort aged  60 years. 
In a subsequent hospitalized cohort studied three months 
after stroke, PSD was found in 26% (66/251).33 The identi-
ﬁ  ed lower frequency of PSD in this study may be related 
to exclusion of patients with persistent aphasia, patients 
with persistent disturbed consciousness, recurrent stroke, 
age  75 years, and the uses of DSM–VI as well as CASI 
and MMSE in the diagnosis of PSD.
In the present study, attention, orientation, calculation, 
language, and motor skills, logical memory, associate 
learning, visual reproduction, drawing, and abstract thinking 
were signiﬁ  cantly involved in PSD. It has been suggested 
that there is no consistent phenotype for stroke-related 
Table 2 Neuroimaging brain ﬁ  ndings and type of stroke in demented and nondemented patients
Neuroimaging ﬁ  ndings (n = 81) Demented 
group (n = 17)
Nondemented 
group (n = 64)
P-value
Type of stroke
Ischemic stroke (n = 68) 13 (76.5%) 55 (85.9%) 0.670
Hemorrhagic stroke (n = 13) 4 (23.5%) 9 (14.1%) 0.020
Size of infarction
Large size of infarction (n = 10) 5 (29.4%) 5 (7.8%) 0.001
Small size infarctions (n = 32) 6 (35.3%) 26 (40.6%) 0.870
Lacunar infarctions (n = 26) 6 (35.3%) 20 (31.2%) 0.750
Circulatory system
Anterior circulation (n = 46) 12 (70.6%) 34 (53.1%) 0.050
Posterior circulation (n = 9) 1 (5.9%) 8 (12.2%) 0.080
Undeﬁ  nite (n = 13) 4 (23.5%) 9 (14.1%) 0.056
Level of infarction
Superﬁ  cial infarction (n = 13) 3 (17.6%) 10 (15.6%) 0.082
Deep infarction (n = 55) 10 (58.8%) 45 (70.3%) 0.088
Cerebellar hemorrhage (n = 5) 1 (5.9%) 4 (6.3%) 0.75
Cerebral hemorrhage (n = 8) 3 (17.6%) 5 (7.8%) 0.05
Lateralization
Dominant hemisphere (n = 20) 7 (41.2%) 13 (20.3%) 0.01
Nondominant hemisphere (n = 61) 10 (58.8%) 51 (79.7%) 0.082
Mechanism of stroke
Large artery atherosclerosis (n = 27) 7 (41.2%) 20 (31.2%) 0.01
Cardioembolic (n = 4) 2 (11.8%) 2 (3.1%) 0.001
Small artery atherosclerosis or lacunar (n = 23) 4 (23.5%) 19 (29.7%) 0.088
Infarcts of undetermined cause (n = 16) 0 16 (25%)  0.0001
Hemorrhagic (n = 13) 4 (23.5%) 9 (14.1%) 0.01
Notes: Data are expressed as number and percentage; signiﬁ  cance is between demented and nondemented groups; signiﬁ  cance is set at p-value   0.05.Neuropsychiatric Disease and Treatment 2009:5 110
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cognitive dysfunction because strokes can strike any region 
of the brain. If selected impaired cognitive functions are 
considered, 50%–75% of stroke patients are found to be 
affected, depending on age.17 The signiﬁ  cant prolongation 
P300 latencies of ERPs at three months after stroke onset, 
further supports the involvement of selected cognitive 
domains in PSD. The intracerebral origin of the P300 is 
poorly understood but most likely reﬂ  ects the summation 
of multiple, simultaneously occurring cognitive and brain 
processes that are engaged during the active processing of 
behaviorally signiﬁ  cant stimulus events and functionally 
linked to 1 resource allocation and memory updating 
operations in the brain. The hippocampus, thalamus, and 
frontal cortex are considered as possible locations of 
the P300 generators,34 these structures are important for 
learning and memory. P300 latency has been found to 
increase as the dementia symptoms increase. P300 latency 
is considered a consequence of attention process, speed 
of reaction, and immediate memory. The shorter P300 
latencies indicate superior mental performance relative to 
longer latencies.25
In the present study, demographic determinants for PSD 
included increasing age, low level of education, and family 
history of dementia. The risk of PSD increased with aging. 
Increasing age is an important risk factor for vascular diseases 
including CVS and vascular dementia. It has been recently 
suggested that an age-related decrease in the buffering 
capacities of both the vessels and the craniospinal cavity 
favors cerebral hypoxia and reduction in cerebral arterial 
inﬂ  ow. The decreased total cerebral blood ﬂ  ow and the 
reduced proportional aqueductal and cervical cerebrospinal 
ﬂ  uid pulsations are the result of arterial loss of pulsatility.35 
The decreased cerebral blood ﬂ  ow with age is a factor for 
brain damage and cognitive decline. The increased risk of 
dementia in older females is consistent with some studies.36,37 
Menopause is known to be associated with cognitive impair-
ment. The estrogen depletion with age increases the incidence 
of vascular dementia.37
Patients with low levels of education were more 
vulnerable to PSD than educated patients. Recent reports 
conﬁ  rmed a real association between educational attainment 
and the risk of dementia 50 to 60 years later.38 It seems that 
Table 3 Comparison between patients (at onset and after three months) and control subjects in cognitive functions
Cognitive functions Patients (Baseline) Patients (After 3 months) Controls (Baseline) Controls (After 3 months)
MMSE 25.58 ± 2.95 22.77 ± 2.53## 25.72 ± 2.1 26.04 ± 1.9
WMS-R
Digit forward 5.58 ± 2.41 4.09 ± 1.19# 6.36 ± 0.99 6.54 ± 0.98
Digit backward 3.72 ± 1.45 2.30 ± 1.52# 4.68 ± 0.99 4.68 ± 0.99
Mental control 3.57 ± 1.07 3.51 ± 1.16 3.08 ± 1.49 3.09 ± 1.54
Logical memory I 11.11 ± 2.79 11.16 ± 2.52 11.58 ± 2.19 11.43 ± 2.41
Logical memory II 10.50 ± 1.50** 11.80 ± 1.70# 13.80 ± 2.00 13.50 ± 1.50
Associate learning 13.45 ± 3.44*** 11.85 ± 2.90### 16.72 ± 3.28 17.00 ± 2.11
Visual reproduction I 3.43 ± 1.19 2.35 ± 1.24# 3.76 ± 0.44 3.64 ± 0.34
Visual reproduction II 3.45 ± 1.30 2.48 ± 1.35# 3.85 ± 0.75 3.73 ± 0.44
CASI
Logical memory 8.00 ± 1.96 6.10 ± 1.85# 8.6 ± 1.70 8.5 ± 1.82
Short memory 9.75 ± 3.48 10.24 ± 3.11 10.50 ± 3.35 10.76 ± 3.32
Attention 8.89 ± 0.65 6.83 ± 0.63# 9.40 ± 1.68 8.6 ± 2.3
Mental manipulation 6.38 ± 2.43 6.67 ± 4.2.32 7.31 ± 2.74 7.43 ± 2.34
Orientation 11.76 ± 4.14** 9.98 ± 4.44## 14.12 ± 3.94 14.10 ± 2.54
Drawing 5.71 ± 3.57** 4.53 ± 3.71# 7.00 ± 3.87 7.80 ± 3.80
Fluency 7.89 ± 2.65*** 7.83 ± 2.80 9.98 ± 2.92 10.50 ± 1.43
Language 7.03 ± 1.83 7.01 ± 1.80 7.88 ± 1.48 7.85 ± 1.22
Abstract thinking 10.64 ± 2.45** 9.51 ± 2.65# 13.58 ± 3.05 13.32 ± 2.32
Total CASI score 80.70 ± 12.72* 72.73 ± 18.34# 88.70 ± 12.75 88.40 ± 12.34
Notes: Data are expressed as mean ± SD; *P   0.05,***p   0.0001,**P   0.01: Base line assessment patients at onset versus controls; #p   0.05, ##p   0.01, ###p   0.01: Before 
treatment assessment versus after treatment.
Abbreviations: MMSE, Mini-Mental State Examination; WMS-R, Wechsler Memory Scale-Revised; CASI, Cognitive Abilities Screening Instruments.Neuropsychiatric Disease and Treatment 2009:5 111
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patients with higher educational attainment have larger 
functional cognitive reserve and also differences in lifestyle 
and risk factor proﬁ  le which are protective against cognitive 
decline. Low levels of education were found to be associated 
with signiﬁ  cant decline in incidental memory, psychomotor 
performance and perception.39 Animal studies conﬁ  rmed that 
complex environmental stimuli promote dendritic growth 
and brain weight.36
The relation between genetic factor and development 
of dementia in elderly has been previously reported.36 In 
accordance with this study, higher percentage of PSD was 
identiﬁ  ed among patients with family history of dementia 
(35.3%) than in the nondemented group (1.6%).
In the present study, large infarcts, lacunar infarcts, domi-
nant hemispheric lesions and motor and functional disability 
were more frequent among patients with PSD. Signiﬁ  cant 
inverse association was identiﬁ  ed between PSD and small 
and lacunar infarcts and severity of stroke.
The size, laterality, location of lesion(s) with particular 
reference to the extent of white matter damage, vascular 
territory involvement, hemispheric and cortical involvement 
are known as important determinants of cognitive 
dysfunction.31 The classic concept implies that dementia of 
vascular origin is the result of a critical volume of infarcted 
brain tissue, irrespective of its topography.40 PSD is well 
documented in patients with extensive subcortical white 
matter lesions.31,40 Large sized infarctions are expected to 
produce more cognitive impairment compared to small sized 
infarction unless the small infarcts are in strategic locations 
(eg, thalamus, corpus callosum, hippocampus) even when 
they are lacunar as identiﬁ  ed also in this study.17,41 Vinters 
and colleagues42 recently described three pathogenic 
concepts of vascular dementias based on pathological and 
functional imaging data as follow: accumulated cortical 
infarcts; strategic subcortical infarcts and functional cortical 
disconnection.
Hemispheric dominance involvement was more frequent 
in patients with PSD. Several studies suggest that intelligence 
or cognitive efﬁ  ciency relies heavily on the integrity of 
language processing and hemispheric dominance. Certain 
cortical lesions due to CVS may generate deﬁ  ned cognitive 
signs and symptoms (amnesia, aphasia, apraxia, alexia, 
agraphia). In combination with noncognitive abnormalities, 
such as emotional instability or loss of initiative, these lesions 
in various combinations and extensions may constitute a 
cortical dementia syndrome.43,44 Ballard and colleagues44 
reported that the severity of expressive language performance 
at three months was associated with dementia at follow-up. 
In general, the degree of PSD commonly parallel that of 
motor and functional disability,30–32 however, some studies 
demonstrated that the degree of dementia did not always 
parallel that of neurological deﬁ  cits.45
Although many studies have been conducted for 
identiﬁ  cation of vascular risk factors for PSD, however, their 
ﬁ  ndings were inconsistent and controversial. In this study, 
current smoking, hypertension, AF, IHD, carotid stenosis 
and elevated Hcy levels were more frequent in patients with 
PSD. Signiﬁ  cant inverse association was identiﬁ  ed between 
PSD, smoking, and hypertension.
Current smoking was signiﬁ  cantly associated with PSD. 
Recent studies revealed that smoking was associated with 
greater risk of poor memory in middle-aged and elderly 
individuals and ex-smokers had a lower risk of poor cognition. 
In multicenter cohort studies, higher rates of decline by 
smoking were found in men and women, persons with and 
without family history of dementia, and in three of four 
participating studies. Higher cigarette pack-year exposure 
was correlated with a signiﬁ  cantly higher rate of decline.46–48 
Ikeda and colleagues48 in their prospective case-control study 
conducted to examine the association between cigarette 
smoking and risk of disabling dementia within the cohort 
of 6,343 men and women aged 35–85 years, found that 
Table 4 Event-related potential components in patients (at onset and after three months) and control groups
Item Patients (Baseline) Patients (After 3 months) Controls (Baseline) Controls (After 3 months)
N100 latency (msec) 114.45 ± 37.65 146.84 ± 38.79### 108.84 ± 12.43 111.34 ± 21.21
N200 latency (msec) 235.65 ± 38.12 260.65 ± 39.67### 226.80 ± 13.59 228.99 ± 34.21
P200 latency (msec) 194.02 ± 41.59 213.41 ± 36.41### 183.60 ± 16.19 189.99 ± 20.26
P200 amplitude (mv) 9.26 ± 3.72 8.18 ± 3.36 9.59 ± 8.57 10.32 ± 11.34
P300 latency (msec) 311.17 ± 41.85 330.04 ± 44.26### 314.80 ± 10.50 310.76 ± 9.76
P300 amplitude (mv) 14.36 ± 5.69 17.83 ± 8.43 14.99 ± 8.61 16.89 ± 9.76
Notes: Data are expressed as mean ± SD; *p   0.05, **p   0.01: Baseline assessment patients versus controls; #p   0.05, ##p   0.01, ###p   0.01: Before treatment assess-
ment versus after treatment.Neuropsychiatric Disease and Treatment 2009:5 112
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long-term cigarette smoking was associated with a great risk 
of disabling dementia. Furthermore, and contrary to early 
case-control studies which suggested that smoking protects 
against AD, recent prospective studies have shown that elderly 
who smoke may be at increased risk for dementia. In the 
recent observational study done by Almeida and colleagues,49 
smoking was found to be associated with reduced cortical 
regional gray matter density in brain regions associated 
with AD. Anstey and colleagues50 assessed the association 
of smoking with dementia and cognitive decline in a meta-
analysis of 19 prospective studies with at least 12 months 
of follow-up. Studies included a total of 26,374 participants 
(mean age: 74 years) followed up for dementia for 2–30 years 
and 17,023 participants followed up for 2–7 years. Over the 
follow-up period, current smokers at baseline were found 
to have a high risk for incident AD, vascular dementia, 
and greater yearly declines in MMSE compared with those 
who never smoked. Recent studies showed that smoking is 
signiﬁ  cantly associated with low cerebral blood ﬂ  ow which 
compromises cognition.51
Hypertension was signiﬁ  cant following PSD. Hypertension 
is an important risk factor for cerebrovscular diseases includ-
ing stroke and also have a role in the development of vascular 
cognitive impairment and vascular dementia.52 An association 
between hypertension and reduced blood ﬂ  ow and vascular 
dementia was documented.53,54 Studies pointed out that blood 
pressure levels should be kept within a certain range (below 
140/90 mmHg) for prevention of cardiovascular, cerebrovas-
cular damage and maintaining cerebral perfusion enough to 
preserve cognitive ability and prevention of some types of 
dementia.54 Longitudinal studies have suggested that hyper-
tension in midlife is associated with cognitive impairment 
in later life.53
Atrial ﬁ  brillation (AF) was frequent in patients with PSD 
but not signiﬁ  cantly associated with PSD. AF does not only 
result in thromboembolism but also reduce cardiac output. 
Cardiac output reduction is greater at faster ventricular rates 
and could result in cerebral hypoperfusion. Failure to main-
tain adequate brain perfusion might be a second mechanism 
of brain damage and cognitive decline.55
In general and consistent with the results of the present 
study, although IHD was more frequent in patients with 
PSD but had no signiﬁ  cant association with it. This indicates 
greater systemic vascular damage and functional impairment 
in patients.56
Carotid stenosis was more frequent in patients with PSD 
but the degree of stensosis was not signiﬁ  cantly associated 
with cognitive decline. Recent studies revealed that common 
carotid artery intima-media thickness (CCA-IMT) predicts 
an increased risk for cognitive impairment, particularly poor 
Table 5 Demographic, clinical data, vascular risk factors according to the tHcy levels
Variables Low tHcy 
(  12 μmol/L) (n = 59)
High tHcy 
( 12 μmol/L) (n = 22)
P-value
Age (years) 55.5 ± 9.2 65.9 ± 10.3 0.005
Males/females (n = 27/54) 20/39 7/15 0.554
Current smoking (n = 37) 17 (45.9%) 20 (54.1%) 0.75
Hypertension (n = 33) 15 (45.5%) 18 (54.5%) 0.64
Atrial ﬁ  brillation (n = 6) 3 (50%) 3 (50%) 0.85
Ischemic heart disease (n = 17) 7 (41.1%) 10 (58.8%) 0.075
Carotid stenosis (n = 21) 5 (23.8%) 16 (76.2%)  0.0001
Type of stroke
Infarction (n = 68) 52 (76.5%) 16 (20.5%) 0.670
Hemorrhage (n = 13) 7 (53.8%) 6 (46.2%) 0.082
Size of infarction
Large size of infarction (n = 10) 3 (30%) 7 (70%)  0.0001
Small size infarctions (n = 32) 27 (84.4%) 5 (15.6%)  0.0001
Lacunar infarctions (n = 26) 16 (61.5%) 10 (38.5%) 0.001
Post-stroke dementia (n = 17) 6 (35.3%) 11 (64.7%)  0.0001
P300 latency (delayed) 311.05 ± 44.36 330.04 ± 45.50 0.008
Depression (n = 20) 12 (60%) 8 (40%) 0.075
Notes: Data are expressed as mean ± SD and number (%); signiﬁ  cance between low and high homocysteine levels; signiﬁ  cance is set at p-value   0.05.Neuropsychiatric Disease and Treatment 2009:5 113
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memory and cognitive speed, in elderly women.57 Talelli 
and colleagues58 reported signiﬁ  cant inverse association 
between the CCA-IMT and vascular cognitive decline 
assessed by MMSE after 12 months of ischemic stroke after 
adjustment for other relative risk factors. Lee and Yeh59 
reported signiﬁ  cant inverse association between the severity 
of intracranial arteries stenosis as detected by CCA-IMT and 
vascular cognitive decline assessed by CASI testing after 
three months of ischemic stroke. Severe transient attacks 
of ischemia as occur with carotid artery stenosis commonly 
result in infarction of the watershed areas present in the 
cerebral cortex and deep white matter. Watershed areas are 
most sensitive to hypoxia, but because the cortex has a lower 
threshold for ischemia and a higher metabolic demand, severe 
transient ischemia commonly results in infarction in cortical 
areas more readily than in deep white matter.60
Although 24.7% of our patients had depression but the 
latter was not signiﬁ  cantly associated with PSD. Depression is 
a common sequela in stroke with a reported frequency of up to 
65% of all patients.61 Cognitive deﬁ  cits could be a cause or a 
consequence of depression. Kimura and colleagues61 observed 
that treatment of stroke patients with nortriptyline resulted in 
cognitive improvement while others found the reverse.62
In the present study, a signiﬁ  cant number (27.2%) of stroke 
patients had elevated levels of Hcy. Compared to patients with 
low Hcy levels, older ages, smoking, sizable infarctions and 
carotid stenosis were signiﬁ  cantly associated with higher Hcy 
levels. Recently, accumulating evidence from several studies 
suggested that raised concentrations of plasma Hcy have been 
associated with the risk of atherosclerosis and coronary, cerebral 
and peripheral vascular disease.15,63,64 Mild hyperhomocystein-
emia (HHcy) increases in frequency from 5%–7% in the general 
population to 30% of patients with coronary artery disease and 
42% of patients with CVS.65 In this study, Hcy was a risk factor 
of ischemic or hemorrhagic strokes, which is consistent with 
some studies.15,66,67 Boysen and colleagues66 found a signiﬁ  cant 
difference in total Hcy levels between patients with ischemic 
and hemorrhagic stroke, suggesting that elevated total homo-
cysteine is not only a reaction to acute illness but also a risk 
factor for recurrent stroke. Hcy has also been implicated in 
small vessel disease, with an increased risk of leukoaraiosis.15,67 
The mechanism of HHcy-related vascular injury is a subject of 
much research. Dysregulation of Hcy increases the propensity 
for thrombosis, impaired thrombolysis, increased production 
of hydrogen peroxide, endothelial dysfunction and increased 
oxidation of low-density lipoprotein.68
The relationship between Hcy and PSD is uncertain and 
results of different studies are conﬂ  icting. In the present 
study, nearly half of the patients with PSD had HHcy (47.1% 
compared to 22% for nondemented patients). Patients with 
HHcy scored lower on MMSE and CASI but involvement 
of any speciﬁ  c cognitive domain was not identiﬁ  ed with 
elevated Hcy, however, delayed P300 latency of ERPs 
which was also significantly associated with high Hcy 
levels indicated poor attentional process, impaired speed of 
reaction and immediate memory. Cross-sectional analyses, 
longitudinal studies and several community-based studies 
showed that HHcy were significantly related to poorer 
performances at all neuropsychological tests.17,69–71 Dufouil 
and colleagues71 observed that the odds of cognitive decline 
was 2.8-fold (p   0.05) higher in subjects with Hcy levels 
above 15 μmol/L compared with those with Hcy levels below 
10 μmol/L. Seshadri and colleagues17 reported that increase 
in plasma Hcy over 14 uM double the risk of AD.
In univariate analysis, Hcy was inversely associated with 
age, smoking, infarction size and carotid stenosis. Prins and 
colleagues70 found that HHcy was associated with lower 
scores for psychomotor speed, memory function and global 
cognitive function in a population-based study of 1,077 
nondemented elderly. In the prospective study of Folsom 
and colleagues,72 the authors found an association between 
smoking and HHcy and suggested that smoking may reduce 
vitamin B6 in the body, which is one of vitamins involved in 
the mechanisms for Hcy metabolism. Smoking induces deple-
tion of cellular antioxidant and is also known to be associated 
with an increased Hcy level. In addition, exposure to tobacco 
smoke has negative impact on the folic acid level. Folic acid 
is cofactor by demethylation of Hcy to nontoxic methionine.73 
Eikelboom and colleagues74 found a signiﬁ  cant association 
between plasma Hcy levels and ischemic stroke due to large 
artery disease and small artery disease compared with control 
subjects and ischemic stroke due to cardioembolic or other 
etiologic subtypes of ischemic stroke. However, Hcy levels 
were not signiﬁ  cantly associated with carotid stenosis. Samson 
and colleagues75 suggested that high plasma homocysteine 
concentrations did not play a signiﬁ  cant role in the develop-
ment of restenosis following carotid endarterectomy.
In multiple logistic regression analysis, Hcy increased 
the odds for cognitive impairment after adjustment of other 
relevant risk factors that were signiﬁ  cantly associated with 
it in univariate analysis (as age, smoking, infarction size 
and carotid stenosis). Lehmann and colleagues76 found Hcy 
to be an independent predictor for MMSE scores in elderly 
persons after correcting for age, B12, and folate levels. 
After adjusting for age and gender but not hypertension, 
Sachdev and colleagues77 reported that high plasma Hcy Neuropsychiatric Disease and Treatment 2009:5 114
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( 12.4 μmol/l), was associated with an increased risk of 
developing silent brain infarctions in AD.
The results of this study and others suggested that the 
effect of Hcy on cognitive function is of major signiﬁ  cance 
in patients with CVS, irrespective to the presence of other 
relevant risk factors. Direct neurotoxic effect of Hcy may be 
responsible for cognitive impairment in stroke patients. In 
support: 1) cross-sectional studies have found an inverse rela-
tionship between elevated Hcy levels and cognitive function 
in healthy populations;70 2) it has been recently hypothesized 
that cerebrovascular disease is omnipresent and the crucial role 
of microvascular alterations increasingly recognized in late 
dementia or “Alzheimer syndrome”;78 3) it has been found that 
elevated Hcy is associated with brain atrophy and white matter 
lesions;79 4) recently, HHcy in elderly patients with mental ill-
ness is found to be mainly due to concomitant vascular disease 
and is not related to the speciﬁ  c psychogeriatric diagnosis;80 
and 5) the cognitive impairment is not necessarily explained by 
increased CVS or by lower folate or vitamin B12 levels.74
It has been found that high Hcy levels are responsible 
for over stimulation of the glutamate-binding site of 
N-methyl-D-aspartate (NMDA) receptors, which in turn 
promotes oxidative damage to neurons.81 Direct toxicity 
on glutamate neurotransmission and vascular endothelim, 
indirect inhibition of transmethylation reactions in brain and 
potentiation of amyloid neurotoxicity and promotion of tau 
phosphyrylation are potential mechanisms of Hcy-induced 
cognitive dysfunction.82
The possibility that Hcy being a risk factor for cognitive 
impairment after stroke leads to important therapeutic impli-
cations as HHcy can be corrected with vitamin supplemen-
tation.18 HHcy linked with cognitive impairment might be 
an indirect marker for low concentrations of vitamin B12, 
vitamin B6, or folate, resulting from low intake or from an 
impaired transport of the vitamins to the brain. Although 
the levels of folic acid and Vitamin B were not evaluated 
in this study, however, the possibility of insufﬁ  cient dietary 
intake due to low socioeconomic status of patients can not be 
excluded as cause of HHcy. Multicenter randomized trials for 
stroke prevention determined that vitamin B supplementation 
is able to reduce the incidence of recurrent vascular events 
in patients with stroke or transient ischemic attacks and 
dementia.83 Hcy-lowering treatment proved to be effective 
in prevention of cognitive deﬁ  cits secondary to stroke and 
several neuropsychiatric disorders in retrospective studies. 
Schroecksnadel and colleagues84 documented that the use of 
antioxidant vitamins and anti-inﬂ  ammatory drugs reduced the 
levels of Hcy and also the risk for vascular dementia.
The current study has some limitations: a) it did not include 
sufﬁ  cient number of patients. It involved only a hospital-based 
sample; b) there were no historical dietary data; c) no evaluation 
for the levels of folic acid or vitamin B12 or vitamin B6 was 
done; and d) we did not do high resolution MRI brain scan for 
patients (due to the limited facilities at our hospital) as silent 
brain infarctions may be a confounding variable for marked 
and progressive cognitive decline.
Conclusions
This study indicated that cognitive decline is a common 
adverse consequence after CVS. Better knowledge of the 
risk factors for PSD should increase the effectiveness of 
preventive strategies for patients with stroke. A signiﬁ  cant 
inverse relationship was identiﬁ  ed between Hcy and cogni-
tion despite the presence of other relevant risk factors for 
stroke. It is possible that cognitive impairment may result 
from CVS and its related vascular risk factors including 
the direct association with high Hcy levels. Longer follow 
up studies in large sample size are necessary to determine 
the impact of Hcy on progression of post-stroke cognitive 
impairment. Because HHcy is a potentially reversible risk 
factor and can be identiﬁ  ed early, prospective intervention 
studies should investigate whether lowering Hcy levels by 
vitamin supplementations could reduce the incidence and 
progression of cognitive decline after stroke.
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